CLL develops slowly, creating defective white blood cells that can’t produce antibodies against infection. The average age of patients at diagnosis is 72. As more people age, more will develop CLL.
We’re leading the attack against CLL by using new targeted therapies to combat relapsed or resistant disease. We’re launching innovative combination clinical trials and applying immunotherapy to find and kill cells that survive initial treatment.
New knowledge and progress-enabling technologies make this the time to reduce cancer deaths. MD Anderson's comprehensive Moon Shots Program capitalizes on these novel resources as it builds on a 70-plus-year history of renowned expertise, lifesaving innovation and global impact.Learn more